SCHEMBL5666405

SCHEMBL5666405

O=C1[N]C2(CCN(C(=O)c3cccc(C(F)(F)F)c3)CC2)NC1Cc1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.58
GAA P10253 1/20 0.58
CYP2C19 P33261 1/20 0.58
SMN1; SMN2 Q16637 1/20 0.49
LMNA P02545 1/20 0.48
POLB P06746 1/20 0.48
HPGD P15428 1/20 0.48
ALDH1A1 P00352 2/20 0.48
USP2 O75604 3/20 0.47
MGLL Q99685 1/20 0.47
TACR1 P25103 1/20 0.46
RBP4 P02753 1/20 0.46
HSD11B1 P28845 1/20 0.45
PKLR P30613 1/20 0.45
MAPK8 P45983 1/20 0.44
MAPK10 P53779 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3997343 0.83 NAMPT (0.42) CYP3A4CYP2C19SMN1; SMN2LMNAALDH1A1
SCHEMBL5669833 0.83 LMNA (0.47) CYP3A4GAACYP2C19SMN1; SMN2LMNA
SCHEMBL5671665 0.83 NPC1 (0.51) GAALMNAPOLBHPGDALDH1A1
SCHEMBL4003425 0.82 KMT2A (0.45) GAALMNAPOLBHPGDALDH1A1
SCHEMBL3999620 0.81 MAPK1 (0.46) CYP3A4CYP2C19SMN1; SMN2LMNAPOLB
SCHEMBL4001386 0.81 MEN1 (0.42) CYP3A4CYP2C19SMN1; SMN2LMNAMGLL
SCHEMBL2942520 0.81 CYP3A4 (0.58) CYP3A4GAACYP2C19SMN1; SMN2LMNA
SCHEMBL5668948 0.80 CYP2C19 (0.46) CYP3A4GAACYP2C19ALDH1A1USP2
SCHEMBL3997334 0.80 MGLL (0.47) SMN1; SMN2HPGDALDH1A1MGLL
SCHEMBL4000176 0.79 CA1 (0.59)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1730147-A1 SUBSTITUTED 1,4,8-TRIAZASPIRO[4,5]DECAN-2-ON COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY Grünenthal GmbH (DE) 2006-12-13 EP disclosed
WO-2005095402-A1 SUBSTITUTED 1,4,8-TRIAZASPIRO[4.5]DECAN-2-ON COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY Grünenthal GmbH (DE) 2005-10-13 WO disclosed